Cara Therapeutics Inc Forecast, price target & analysts
Cara Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Cara Therapeutics Inc Classifications & Recommendation:
Cara Therapeutics Inc Price Target
| Target Price | $12.00 |
| Price | $4.95 |
| Potential |
142.42%
register free of charge
|
| Number of Estimates | 2 |
|
2 Analysts have issued a price target Cara Therapeutics Inc 2026 .
The average Cara Therapeutics Inc target price is $12.00.
This is
142.42%
register free of charge
$12.00
142.42%
register free of charge
$12.00
142.42%
register free of charge
|
|
| A rating was issued by 5 analysts: 1 Analysts recommend Cara Therapeutics Inc to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cara Therapeutics Inc stock has an average upside potential 2026 of
142.42%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.14 | 7.83 |
| 65.95% | 9.61% | |
| EBITDA Margin | -778.57% | -830.37% |
| 34.66% | 6.65% | |
| Net Margin | -994.01% | -553.55% |
| 73.69% | 44.31% |
2 Analysts have issued a sales forecast Cara Therapeutics Inc 2025 . The average Cara Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Cara Therapeutics Inc 2025 . The average Cara Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
The average Cara Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $-71.0m | 40.86% |
|---|---|---|
| 2025 |
$-43.3m
38.96%
Unlock
|
|
Net Margin
| 2024 | -994.01% | 73.69% |
|---|---|---|
| 2025 |
-553.55%
44.31%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -15.53 | -0.79 |
| 40.86% | 94.91% | |
| P/E | negative | |
| EV/Sales | 0.95 |
The average Cara Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $-15.53 | 40.86% |
|---|---|---|
| 2025 |
$-0.79
94.91%
Unlock
|
|
P/E ratio
| Current | -0.32 | 23.81% |
|---|---|---|
| 2025 |
-0.39
21.88%
Unlock
|
|
Cara Therapeutics Inc...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
